Skip to main content
Premium Trial:

Request an Annual Quote

With Targets from LLNL, Phylos Will Make Hundreds of Binding Proteins Per Quarter

Premium

Joanna Albala, a senior biomedical scientist at Lawrence Livermore National Lab, said her lab’s new partnership with proteomics company Phylos is the outcome of “a true networking opportunity” at last year’s Chips to Hits meeting in Philadelphia. It was there that executives from Phylos, a Lexington, Mass., developer of protein binders, happened to be on the lookout for a collaborator that could custom deliver target proteins. Albala sat down next to one of them during a luncheon in the exhibit hall.

“We’d been buying protein targets from various sources, but the quality is variable and it’s also not cheap,” Phylos president Ashley Lawton told ProteoMonitor. “We felt we needed to find a more controlled source of target proteins” to use as substrates when developing binding agents.

Albala’s experience developing chip and bead-based technologies for understanding protein function, and her proximity to Lawrence Livermore’s massive collection of IMAGE Consortium cDNA clones made her a perfect match for Phylos.

The four-year deal between the lab and the company, announced Oct. 11, will provide Albala with what she says is “significant funding” — to add staff to her lab and to continue work developing a high-throughput process for deriving target proteins from cDNAs. In turn, by early 2002, her team will begin delivering to Phylos on the order of 100 protein targets per quarter.

Profuse proteins

Phylos, a 90-person company that was spun out of Harvard University and Massachusetts General Hospital four-and-a-half years ago, will use its technology to create binding agents against those targets for placement on protein chips.

Developed in a partnership with Aventis Research and Technology, Phylos’ automated PROfusion platform expresses a library of trillions of different covalently linked nucleic acid-protein molecules, and uses PCR to fish out the molecules that bind with the target proteins.

Lawton, a former VP of operations at Genzyme, described the technology as an “efficient way of finding binding proteins like antibodies that have the exact characteristics you want.” The quantities of targets being delivered by Albala and crew will enable Phylos to output hundreds of binding proteins per quarter, Lawton said.

Phylos intends to market the resultant binders to makers of protein chips. “We believe there is a shortage of good quality content, inhibiting good quality microarrays,” Lawton said, naming as potential customers companies such as Zyomyx, that could use binding proteins to make microarrays, or pharmaceutical and biotechnology companies that make in-house arrays.

Lawton cites analysts who project the market for protein microarrays to reach $1 billion to $5 billion a year within the next 5 to 10 years. But if that side of the business doesn’t take off, he said, Phylos has also started to build a preclinical group that will identify therapeutic targets and create new biotherapeutic molecules.

— AJB

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.